
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇦🇺AU · Courses#1415K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2.5K to 15K🎙 ~2x weekly·61 episodes·Last published 4d ago - Monthly Reach
Unique listeners across all episodes (30 days)
5K to 30K🇦🇺100% - Active Followers
Loyal subscribers who consistently listen
2K to 12K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
ASSETS-NY – Anal Dysplasia Screening, Surveillance, Education and Treatment Services of NY
May 28, 2026
22m 37s
Introducing Point-of-Care Testing for Hepatitis C
May 14, 2026
21m 35s
Cannabis and Pregnancy
Apr 20, 2026
22m 41s
CROI 2026 – Live from Denver: What You Need to Know
Apr 7, 2026
15m 13s
Misconceptions about Contraception
Mar 12, 2026
33m 32s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/28/26 | ![]() ASSETS-NY – Anal Dysplasia Screening, Surveillance, Education and Treatment Services of NY | Host Marguerite Urban, MD is joined by William DeWitt, MD, Clinical Director of Anal Health in Primary Care at Northwell Health, to discuss a new coalition forming in New York City about anal dysplasia. ASSETS-NY aims to bring together people in this field and harness momentum to drive further research and implementation of anal dysplasia and cancer screening, surveillance, education and treatment in New York State. Be sure to check out the coalition’s website at https://www.screenyourbutt.org/nyc/. Related Content: CEI Line: 1-866-637-2342 www.ceitraining.org www.hivguidelines.org ASSETS-NY Website: https://www.screenyourbutt.org/nyc/ NYS DOH AIDS Institute, “Screening for Anal Dysplasia and Cancer in Adults With HIV” guidelines: https://www.hivguidelines.org/guideline/hiv-anal-cancer/#toc_wurop7uf International Anal Neoplasia Society (IANS): https://www.iansoc.org/ | 22m 37s | ||||||
| 5/14/26 | ![]() Introducing Point-of-Care Testing for Hepatitis C | New York State’s Hepatitis C Dashboard shows that in 2023, 4,783 people were newly diagnosed with HCV in the state, an 8% decrease from 2022. Incidence also decreased, with the rate of new HCV infections dropping from 4.0 to 3.6 per 100,000 population among adult New Yorkers. Despite these gains, progress towards elimination has been stalled by reliance on a multi-step diagnostic algorithm to confirm viremia. In populations with the highest risk of infection – including people who inject drugs – testing and treatment are often inaccessible due to barriers along the care cascade. On June 27, 2024, the U.S. Food and Drug Administration authorized the first point-of-care (POC) HCV RNA test that can be performed where a person receives care, like an outpatient clinic or mobile unit. The availability of a POC HCV RNA testing, which can provide a qualitative results in 60 minutes, unlocks New York’s ability to integrate a test-and-treat approach where a person can be tested for HCV, and if positive for HCV RNA, be linked to care and potentially receive treatment during the same health care visit. To achieve elimination goals, simplified care that engaged people who inject drugs is essential, and single encounter testing and treatment offers a new tool to significantly expand access, decrease time from diagnosis to treatment and increase the number of New Yorkers who are treated for HCV. Today’s episode will focus on this new diagnostic tool and its potential impact on HCV elimination across New York. Related Content: New York State Department of Health Clinical Guidelines Program, Hepatitis C Virus Screening, Testing, and Diagnosis in Adults (January 2023): https://www.hivguidelines.org/guideline/hcv-testing/?mycollection=hepatitis-care New York State Department of Health Hepatitis C Dashboard: https://hcvdashboardny.org/ New York State Department of Health, Frequently Asked Questions for Hepatitis C Point of Care Diagnostic Testing (June 2025): https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/providers/docs/poc_faq.pdf Erie County Medical Center’s Center for Hepatology Care (La Bodega): https://medicine.buffalo.edu/news_and_events/news/2020/04/martinez-bodega-hepatology-clinic-10699.html U.S. Food and Drug Administration News Release, FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test (June 2024): https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-point-care-hepatitis-c-rna-test MacIsaac MB, et al. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility. Int J Drug Policy. 2024 March:125:104317. doi:10.1016/j.drugpo.2024.104317. Point-of-care HCV RNA testing how to video: https://vimeo.com/1172653335?fl=ip&fe=ec | 21m 35s | ||||||
| 4/20/26 | ![]() Cannabis and Pregnancy | Based on data from 2023-24, roughly 23% of New Yorkers aged 21 or older reported cannabis use in the past 12 months. Although men generally have a higher prevalence of use than women, recent studies show a narrowing gap as female consumption rises. Despite this trend, research is sorely lacking on the impact of cannabis use on pregnancy, birth outcomes and overall health. Many advisory panels and organizations advise against the use of cannabis during pregnancy, but there are numerous reasons pregnant people choose to use. On today’s episode, we’ll talk through the evidence and provide best practices for caring for pregnant persons who use cannabis. Related Content: New York State Department of Health Clinical Guidelines Program Therapeutic Use of Medical Cannabis in New York State (October 2025): https://www.suguidelinesnys.org/guideline/med-cannabis/?mytab=tab_6/#pregnancy New York State Department of Health Office of Cannabis Management Cannabis Considerations for Pregnant and Breastfeeding/Chest Feeding Individuals (2022): https://cannabis.ny.gov/system/files/documents/2022/07/cannabis-considerations-for-pregnant-and-breastfeeding-chestfeeding-individuals-fact-sheet_v2.pdf New York State Behavioral Risk Factor Surveillance System Brief (November 2024-05): https://www.health.ny.gov/statistics/brfss/reports/docs/2024-05_brfss_cannabis_use.pdf New York State Office of Cannabis Management Cannabis Education Library: https://cannabis.ny.gov/education Zolotov Y, Mendoza Temple L, Isralowitz R, et al. Developing Medical Cannabis Competencies: A Consensus Statement. JAMA Netw Open. 2025;8(10):e2535049. doi:10.1001/jamanetworkopen.2025.35049 Raz M, Gupta-Kagan J, & Asnes A. THC Ingestions and Child Protective Services: Guidelines for Practitioners. J Addict Med. 2025 July-Aug;19(4):350-52. doi:10/1097/ADM.0000000000001441 Data to Action: Cannabis consumption during the perinatal period and clinicians’ screening and advising, New York State outside of New York City, 2017-2018 and 2021-2022: https://apps.health.ny.gov/public/tabvis/PHIG_Public/prams/publications/Cannabis_consumption_during_the_perinatal_period.pdf Project CBD: http://projectcbd.com/ American College of Gynecologists and Obstetrics Clinical Consensus on Cannabis Use during Pregnancy and Lactation (October 2025): https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2025/10/cannabis-use-during-pregnancy-and-lactation CEI Training, Clinical Approaches to Medical Cannabis: https://ceitraining.org/courses/1589 CEI Clinical Consultation Line1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. https://ceitraining.org/ | 22m 41s | ||||||
| 4/7/26 | ![]() CROI 2026 – Live from Denver: What You Need to Know | Conference on Retroviruses and Opportunistic Infections (CROI) 2026 took place from February 22 to 25 in Denver, Colorado. CROI is an annual scientific meeting devoted to the understanding, prevention, and treatment of HIV/AIDS and the opportunistic infections associated with AIDS. Thousands of leading researchers and clinicians from around the world convene in each year for the Conference. On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, reflects on this year’s conference and shares his highlights about exciting developments in the world of HIV prevention and treatment. Related Content: CROI University of Liverpool HIV Drug Interactions Checker (website and app) CEI Clinical Consultation Line1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. https://ceitraining.org/ | 15m 13s | ||||||
| 3/12/26 | ![]() Misconceptions about Contraception | Host Dr. Erica Bostick from the University of Rochester Medical Center Division of Adolescent Medicine chats with Dr. Stacy Sun, a double board-certified physician in obstetrics and gynecology and complex family planning at the University of Rochester, about misconceptions they hear from patients about contraception. Should patients get their hormone levels checked before starting a birth control method? What is emergency contraception and how does it work? Is it safe to use contraception to suppress the menstrual cycle? What do recent studies show about the Depo-Provera shot and the risk of meningioma? Listen to this episode to hear all about these common questions and more, and to get real examples of counseling tips from Dr. Bostick and Dr. Sun! Related Content: CEI Line: 1-866-637-2342 https://ceitraining.org/ www.hivguidelines.org Curtis KM, Nguyen AT, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2024.MMWR Recomm Rep 2024;73(No. RR-3):1–77. DOI: http://dx.doi.org/10.15585/mmwr.rr7303a1 Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWRRecomm Rep 2024;73(No. RR-4):1–126. DOI: http://dx.doi.org/10.15585/mmwr.rr7304a1 Xiao T, Kumar P, Lobbous M, Yogi-Morren D, Soni P, Recinos PF, Kshettry VR. Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US. JAMA Neurology. 2025;82(11):1094-1102. doi:10.1001/jamaneurol.2025.3011. Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M, Weill A. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024;384:e078078. doi:10.1136/bmj-2023-078078 | 33m 32s | ||||||
| 2/17/26 | ![]() What “The 72-Hour Rule” Update Means for New York State | Effective February 19, 2026, New York State law permits clinicians to dispense up to 72 hours (equivalent to a 3-day supply) of controlled substances, such as methadone and buprenorphine, for the management of opioid withdrawal while arranging referral and linkage to care for persons with opioid use disorder, as authorized by federal regulations (specifically, the Code of Federal Regulations or CFR number 1306.07). The federal regulations were updated in August 2023, and New York State law is just now catching up. We informally refer to the update as “The 72-Hour Rule.” Featuring Dr. Linda Wang, this episode reviews what this update means for New York State and how clinicians and healthcare administrators can think about its implementation. Are you implementing “The 72-Hour Rule” in clinical practice in New York State? We want to hear from you! Please reach out to share your experience: Lauren.walker3@mountsinai.org. Related Content: New York State Senate Bill S3416D: https://www.nysenate.gov/legislation/bills/2025/S3416/amendment/D Code of Federal Regulations (CFR) § 1306.07: https://www.ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR1eb5bb3a23fddd0/section-1306.07 Skogrand E, et al. (2024). Dispensing methadone at hospital discharge: One hospital’s approach to implementing the “72-hour rule” change. J Addict Med. 2024; 18(1):71-74. doi: 10.1097/ADM.0000000000001246. Shahlapour M, et al. (2024). Novel uses of methadone under the “72-hour rule” to facilitate transitions of care and low-dose buprenorphine induction in an outpatient bridge clinic. J Addict Med. 2024; 18(3):345-347. doi: 10/1097/ADM.0000000000001281. Taylor JL, et al. (2022). Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 2022; 236:109497. doi: 10.1016/j.drugalcdep.2022.109497. CEI Clinical Consultation Line1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. https://ceitraining.org/ | 19m 33s | ||||||
| 1/12/26 | ![]() Two New Treatments for Gonorrhea; one is available now! | In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights the FDA's December 2025 approval of two innovative oral therapies that mark a significant step forward in combating this prevalent sexually transmitted infection. Dr. Fine discusses the first of these treatments, Zoliflodacin (Nuzolvence), a novel medication specifically developed for urogenital gonorrhea. Administered as a single oral dose, it offers patients a convenient and effective option. The second treatment, Gepotidacin (Blujepa), is a versatile drug initially approved in March 2025 for urinary tract infections (UTIs). Now, it has been authorized for urogenital gonorrhea treatment, requiring two oral doses for optimal efficacy. Throughout the episode, Dr. Fine provides insights into the clinical trials, mechanisms of action, and potential impact of these therapies on public health. He also emphasizes the importance of addressing antibiotic resistance in gonorrhea and how these new treatments may help mitigate this growing concern. For more information, listeners can refer to the FDA's official announcement and other resources provided below. Tune in to this episode to learn more about these exciting developments and their implications for the future of infectious disease treatment. Related Content: FDA Approves Two Oral Therapies to Treat Gonorrheahttps://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat-gonorrhea CEI Clinical Consultation Line1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. https://ceitraining.org/ | 15m 20s | ||||||
| 11/20/25 | ![]() PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned | On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV. Subcutaneous lenacapavir is administered twice a year (every six months) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. With patients only needing lenacapavir twice a year for HIV prevention, the field has been optimistic about the potential for lenacapavir to reduce barriers and improve access to PrEP. Since we are still early in the rollout subcutaneous lenacapavir, many providers have questions about how to offer it to their patients—from workflow to billing to managing potential side effects and drug-drug interactions. On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Alex Danforth, PharmD. Alex Danforth is a clinical pharmacist in Rochester, NY. She practices at Trillium Health, a federally qualified health center, where she works with patients and providers to help manage medications and optimize care. Alex currently provides clinical leadership for HIV treatment and prevention programs. Drs. Urbina and Danforth talk about the latest New York State Clinical Guidelines for PrEP, which were updated on October 16th. The new guidelines provide important updates, including subcutaneous lenacapavir. They discuss important considerations for initiating patients on lenacapavir as well as some early lessons learned from implementing lenacapavir in their Rochester- and New York City-based clinics. Related Content: PrEP to Prevent HIV and Promote Sexual Health University of Liverpool HIV Drug Interactions Checker (website and app) CEI Line: 1-866-637-2342 https://ceitraining.org/ | 28m 23s | ||||||
| 11/13/25 | ![]() Keeping an Eye on STIs – Have You Heard of TMVII? | This month, host Dr. Marguerite Urban chats with Dr. Jason Zucker, an adult and pediatric infectious diseases physician at Columbia University and the assistant medical director of the New York City HIV/STI Prevention Training Center, about an emerging fungal infection, Trichophyton mentagrophytes Genotype VII, also known as TMVII. Curious about what clinicians should know about TMVII? Listen now to learn more! Related Content: CEI Line: 1-866-637-2342 www.ceitraining.org www.hivguidelines.org “Notes from the Field: Trichophyton mentagrophytes Genotype VII – New York City, April – July 2024” - https://www.cdc.gov/mmwr/volumes/73/wr/mm7343a5.htm Emerging Sexual Transmission of Trichophyton mentagrophytes Genotype VII Infections, United States - https://wwwnc.cdc.gov/eid/article/31/10/25-1056_article Information for Healthcare Providers: Emerging Ringworm - https://www.cdc.gov/ringworm/hcp/clinician-brief-resistant-infections/index.html | 18m 04s | ||||||
| 10/9/25 | ![]() Recap of the 2025 Annual New York State Hepatitis C and Drug User Health Conference | On September 9th, CEI hosted its first in-person conference dedicated to hepatitis C and drug user health. A group of New York State-based clinicians met in Catskill for a full day agenda focused on (1) integrating wellness into clinical practice as a way to improve patient care and outcomes, and (2) innovative decision-making frameworks to help clinicians navigate complex scenarios in the absence of strong formal evidence, like clinical guidelines and peer reviewed studies. This episode of “Conversations with CEI” features conference planner and facilitator Taylor Edelmann – an educator and consultant working at the intersection of LGBTQIA+ health, drug user health and harm reduction – sharing his experience and insights about the day. Taylor currently oversees the Lighthouse Learning Collective at the National Harm Reduction Coalition, a program focused on supporting LGBTQIA+ harm reductionists and people who use drugs and engage in sex work. As one of the first openly transgender NCAA athletes, Taylor brings a deeply personal lens to his work advocating for gender-affirming care. He regularly provides clinical education and technical assistance to providers across the country, including Yale University and one of Connecticut’s largest federally qualified health centers, and recently presented at the 2025 Harm Reduction International Conference in Bogotá, Colombia. Taylor is also the co-creator of ChemSex Awareness Week, and the lead author of Gender Affirming Harm Reduction: A Toolkit for Syringe Service Programs, the first resource of its kind developed specifically for social service providers in harm reduction settings. Related Content: 2025 Annual NYS Hepatitis C and Drug User Health conference website: https://ceitraining.org/conference/conferences/3 Lighthouse Learning Collective at the National Harm Reduction Coalition: https://harmreduction.org/our-work/action/lighthouse-learning-collective/ Gender Affirming Harm Reduction: A Toolkit for Syringe Service Programs: https://lighthousetoolkit.my.canva.site/ Narrative Medicine: https://www.aamc.org/news/narrative-medicine-every-patient-has-story Drug, Set, and Setting: The Basis for Controlled Intoxicant Use: https://southwestrecoveryalliance.org/wp-content/uploads/2020/02/Drug-Set-and-Setting-Zinberg-N-1.pdf CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. ceitraining.org | 27m 28s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 9/9/25 | ![]() Insights from the 13th International AIDS Society Conference on HIV Science | In this episode of Conversations with CEI, Dr. Steven Fine unpacks some of the latest developments and research presented at the 2025 International AIDS Society (IAS) Conference on HIV Science, held in Kigali, Rwanda. From innovative treatment strategies to advancements in prevention and global health equity, Dr. Fine highlights the pivotal discussions and groundbreaking studies that are shaping the future of HIV care. Tune in to gain a deeper understanding of the strides being made in the fight against HIV and the collaborative efforts driving progress on a global scale. Related Content: The International AIDS Society (IAS) https://www.iasociety.org/conferences/ias2025 Official site for the IAS 2025, 13th IAS Conference on HIV Science, held in Kigali, Rwanda, from July 14-17, 2025. https://www.iasociety.org/blog/takeaways-ias-2025 Takaways from the IAS 2025 Conference CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. www.ceitraining.org | 16m 30s | ||||||
| 8/11/25 | ![]() Evolving Landscape of Geriatric HIV Care | The demographics of HIV care are rapidly changing, and with them, the clinical needs of patients aging with HIV. In this episode, host Dr. Tony Urbina, Medical Director for CEI's HIV Primary Care and Prevention Center of Excellence, sits down with geriatrician Dr. Angela Condo to explore the unique intersection of geriatric medicine and HIV care. Dr. Angela Condo is a board-certified internist and geriatrician at Mount Sinai's Icahn School of Medicine, where she established the Comprehensive Program of Integrated Care for Older Adults with HIV at the Peter Krueger Clinic. With initial support from the Keith Herring Foundation and additional HRSA funding through the Aging with HIV initiative, her interdisciplinary program has been serving patients for five years using an innovative embedded consultation model. Related Content: NYS DOH AI Guidance on Addressing the Needs of Older Patients in HIV Care: https://www.hivguidelines.org/guideline/hiv-aging/ CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. ceitraining.org | 27m 19s | ||||||
| 7/10/25 | ![]() Highlights and Perspectives from the 11th Annual NYS Sexual Health Conference | Live from Canandaigua…it’s the 11th Annual NYS Sexual Health Conference! The CEI Sexual Health Center of Excellence hosted the 11th Annual NYS Sexual Health Conference in-person on Friday May 2, 2025, in beautiful Canandaigua, NY. This was the Center’s second in-person conference since the COVID-19 pandemic and was the Center’s largest in-person event held to-date, bringing together over 225 clinicians and public health professionals from across NYS (and beyond!). In this episode, host Juhua Wu, Director of the University of Rochester Center for Community Practice and team member of the CEI Sexual Health Center of Excellence, checks in live from the conference with four presenters about their experience at the conference, perspectives on what they learned from other sessions, and “need to know” highlights from their own presentations. Join Juhua, along with Rachel Hart-Malloy, PhD, MPH, Brenda Tesini, MD, Michael Brennan, DNP, FNP, and Jeremy Kidd, MD, MPH, for a real-time review of the conference! Related Content: STI Dashboard New York: https://www.stidashboardny.org/ Chemsex: Questions and Answers: https://www.suguidelinesnys.org/guideline/chemsex/ New York State Department of Health, Healthy Sex campaign: https://campaigns.health.ny.gov/SexualHealth University of Rochester Center for Community Practice: www.urccp.org CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. ceitraining.org | 16m 36s | ||||||
| 6/12/25 | ![]() Xylazine & Medetomidine & Nitazines, Oh My! An Update on New York State’s Drug Supply | New York drug overdose deaths and death rates are on the decline, but with significant disparities and the current, toxic drug supply is partially to blame. Harmful additives like fentanyl analogues, xylazine and medetomidine, among others, have been found in cocaine, heroin, MDMA and pressed into pills. Additives are undetectable by sight, taste and smell which increases the risk of overdose for people who use and may not be aware of what’s in their drug supply. This episode features Drs. Sharon Stancliff and Jennifer Love discussing additives commonly found in the New York State supply, including BTMPS, fentanyl analogues, medetomidine, nitazenes and an updates on xylazine. Related Content: New York State Department of Health AIDS Institute Clinical Guidelines Program for Substance Use Care: https://www.suguidelinesnys.org/ New York State Department of Health Drug Checking Program: https://www.health.ny.gov/diseases/aids/consumers/prevention/oduh/drug_checking.htm New York City Department of Health Drug Checking Program: https://www.nyc.gov/site/doh/health/health-topics/alcohol-and-drug-use-services.page New York City Department of Health. Setting Up a Drug-checking Program: A Comprehensive Guide to Implementation. https://www.nyc.gov/assets/doh/downloads/pdf/basas/drug-checking-program-implementation-guide.pdf https://legislativeanalysis.org/wp-content/uploads/2025/03/BTMPS-Fact-Sheet-FINAL.pdf Friedman, JR, et al. (2025) The detection of xylazine in Tijuana, Mexico: Triangulating drug checking and clinical urine testing data. J Addict Med. doi: 10.1097/ADM.0000000000001474 Krotulski, AJ, et al. (2024) Medetomidine Rapidly Proliferating Across USA — Implicated In Recreational Opioid Drug Supply & Causing Overdose Outbreaks, Center for Forensic Science Research and Education, United States. Available from https://www.cfsre.org/images/content/reports/public_alerts/Public_Alert_Medetomidine_052024.pdf New York Medication for Addiction Treatment and Electronic Referrals (MATTERS) Program. Request test strips (for xylazine and fentanyl). Available from: https://mattersnetwork.org/request-test-strips/ New York State Office of Addiction Services and Supports (OASAS). Harm Reduction Delivered (online order for xylazine and fentanyl test strips). Available from: https://oasas.ny.gov/harm-reduction-delivered NEXT Distro. Ordering Supplies (for safer drug use). Available from: https://nextdistro.org/nydistro CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. ceitraining.org | 29m 38s | ||||||
| 5/16/25 | ![]() CEI…we got you! Evolving with the Science | In this episode of Conversations with CEI, we engage with CEI’s clinicians, researchers, and public health experts to explore current and emerging issues in HIV primary care, sexual health, Hepatitis C, and drug user health. From the early days of the HIV epidemic to today’s complex syndemic approach, our experts share valuable insights and practical strategies for translating science into practice. We emphasize the importance of a syndemic approach to care, recognizing the overlapping health needs of patients, particularly in the marginalized population. Through a wide range of training and resources, CEI supports New York State clinicians in delivering comprehensive and inclusive care. Related Content: CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. ceitraining.org | 38m 16s | ||||||
| 5/8/25 | ![]() Navigating Measles Vaccine Recommendations for Patients with HIV | In light of the increase in measles cases within the United States, this episode features Dr. Steven Fine, an infectious disease expert, who offers a comprehensive exploration of the history and progress of measles eradication efforts. Dr. Fine delves into the factors contributing to the resurgence of measles, particularly the role of misinformation in undermining public trust and vaccination efforts. Additionally, Dr. Fine walks us through the latest vaccination recommendations for patients with HIV, addressing the unique considerations required to safeguard this vulnerable group. Tune in to gain valuable insights and practical guidance on current vaccination recommendations aimed at protecting patients with HIV from measles in today's healthcare environment. Related Content: Measles for Health Care Providers: https://www.health.ny.gov/diseases/communicable/measles/providers/ Measles Cases and Outbreaks | Measles (Rubeola) | CDC https://www.cdc.gov/measles/data-research/index.html CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health. ceitraining.org | 20m 06s | ||||||
| 4/10/25 | ![]() The Invisible Latino HIV Crisis | In May 2024, the Centers for Disease Control and Prevention (CDC) released its annual HIV surveillance reports. The new data show a continuation of year-over-year reductions through 2022 in the estimated number of new HIV infections in the United States. But disconcerting trends among Latino people — the country’s second-largest racial or ethnic group after White, non-Latino people — reflect persistent failures in HIV prevention and treatment systems that this overall progress has overshadowed. Related Content: CEI Line: 1-866-637-2342 ceitraining.org | 21m 40s | ||||||
| 3/13/25 | ![]() Updates in Syphilis: Looking Back to Look Forward | Let’s dive in! This month, we welcome new hosts Patrick Passarelli, MD, an infectious diseases fellow at the University of Rochester, and Nicholas Gerbino, a public health professional at the Monroe County Sexual Health Clinic, who take a deep dive into all things syphilis. Dr. Passarelli and Nick discuss history, epidemiological trends, updates and diagnostics, screening strategies, and new studies exploring additional treatment and preventative options for syphilis. Related Content: CDC’s Sexually Transmitted Infections Surveillance, 2023: https://www.cdc.gov/sti-statistics/annual/index.html The Resurgence of Congenital Syphilis in NYS: A Look at the Past and Present to Change the Future: https://cei.podbean.com/e/the-resurgence-of-congenital-syphilis-in-nys-a-look-at-the-past-and-present-to-change-the-future/ Reflections from the 2024 CDC STI Prevention Conference: https://cei.podbean.com/e/reflections-from-the-2024-cdc-sti-prevention-conference/ CEI Line: 1-866-637-2342 ceitraining.org | 34m 19s | ||||||
| 2/13/25 | ![]() The Role of Opioid Treatment Programs in Hepatitis C Care: A Path to Elimination | Between 2010 and 2022 (the latest year for which data are available), 194,375 New Yorkers were diagnosed with hepatitis C (HCV) and of those, 53% (103,213 individuals) are known to have cleared their infection either through treatment or spontaneously. This statistic is worth celebrating, but also highlights the ongoing need for action – the goal outlined in New York State’s Hepatitis C Elimination Plan is to reach 80% by 2030. Furthermore, people who inject drugs are disproportionally affected by HCV – in 2022, 48% of newly reported cases of acute HCV in New York indicated injection drug use as a risk factor. And, when analyzing cases with known risk factors, that figure rose to 81% of newly reported acute cases indicating injection drug use. Providing HCV treatment in opioid treatment program (OTP)s is an innovative and necessary strategy to curb the ongoing epidemic and achieve statewide goals for elimination. This episode features Abigail Hunter, MPH, MSN, FNP-BC, sharing her experience providing HCV treatment at an OTP and recommendations for listeners interested in integrating treatment into clinical services. Related Content: CEI Training “Hepatitis C and Injection Drug Use” - https://ceitraining.org/courses/1148 VOCAL-NY: https://www.vocal-ny.org/ Respectful, Equitable Access to Comprehensive Healthcare (REACH) Program at Mount Sinai: https://www.mountsinai.org/care/primary-care/upper-east-side/ima/reach New York State Department of Health AIDS Institute guideline for the treatment of chronic hepatitis C virus infection in Adults: https://www.hivguidelines.org/hepatitis-care/hcv-treatment/ Taylor, LE. (2020), Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics. Clinical Liver Disease, 16:12-15. https://doi.org/10.1002/cld.921 Addiction Technology Transfer Center Guide to Integrating HCV Services into Opioid Treatment Programs: https://attcnetwork.org/sites/default/files/2020-07/Guide%20to%20Integrating%20HCV%20Services%20into%20Opioid%20Treatment%20-%20July%2024-1.pdf New York State Hepatitis C Elimination Plan: https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/docs/hepatitis_c_elimination_plan.pdf New York State Hepatitis C Dashboard: https://hcvdashboardny.org/ CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/ | 20m 58s | ||||||
| 1/9/25 | ![]() Use of Injectable Cabotegravir for HIV PrEP in Pregnancy | This podcast outlines some of the data presented at the 25th International AIDS Conference from HPTN 084 as it pertains to using injectable cabotegravir for HIV PrEP during pregnancy. Related Content: https://www.hptn.org/research/studies/hptn-084 https://programme.aids2024.org/Programme/Session/349 CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/ | 9m 28s | ||||||
| 12/12/24 | ![]() Compassionate Care for LGBTQ+ Individuals Struggling with Substance Use Disorder | Research suggests that LGBTQ adults have higher rates of substance use and mental health issues, compared to their heterosexual cisgender peers. These health disparities are often related to minority stress—the chronic psychological and emotional strain that people experience due to being part of a marginalized social group. For example, some LGBTQ folks may use alcohol and drugs to cope with internalized homophobia or to self-medicate for anxiety and depression. On the other hand, some people use drugs in the context of social settings and connecting with others in their community. Since not all substance use is unhealthy, how do providers know how to identify when substance use is problematic? And what can physicians do to best support their patients who may be at greater risk for harm or even overdose? On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Eric Kutscher, MD, MSc. Dr. Eric Kutscher is an Assistant Professor of Medicine at the Icahn School of Medicine, where he practices as a primary care and addiction medicine physician at Mount Sinai's Internal Medicine Associates and REACH Program. He currently serves as the Medical Director of the Mount Sinai Hospital Opioid Overdose Prevention Program and Primary Care Lead for the Mount Sinai Center for Transgender Medicine and Surgery. His clinical work and research focus on harm reduction techniques for patients with substance use disorders, particularly within the LGBTQ+ community. Drs. Urbina and Kutscher talk about how providers can identify when substance use is a problem and how to help patients manage substance use disorder, including treatment options and harm reduction strategies. Related Content: 2021-2022 Lesbian, Gay, And Bisexual Behavioral Health A Provider's Introduction to Substance Abuse Treatment for Lesbian, Gay, Bisexual, & Transgender (LGBT) Individuals CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/ | 28m 22s | ||||||
| 11/7/24 | ![]() Reflections from the 2024 CDC STI Prevention Conference | For the first time since 2018 and since the COVID-19 pandemic, the Centers for Disease Control and Prevention hostedtheir biennial STI Prevention Conference in-person in Atlanta, GA from September 16 – 19, 2024. This event broughttogether international leading researchers with government experts, clinical sexual healthcare providers, and state andlocal public health administrators for four days of scientific updates and sessions on science, programs, and policiesrelated to STI care.Dr. Marguerite Urban and Dr. Daniela DiMarco from the CEI Sexual Health Center of Excellence attended the conferenceand are back to bring you insights about their experience at the event. They chat about the different sessions theyattended and share personal thoughts and summaries of the cutting-edge research presented at the conference,focusing on syphilis, Doxy-PEP, gonococcal resistance, and the syndemic of substance use and STIs.Were you unable to attend the conference yourself? Were you there and want to hear our CEI experts’ perspectivesabout some of the sessions? Listen now and let us know what you think by leaving a comment! Related Content: CDC STI Prevention Conference 2024 website: https://stipreventionconference.org/ CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/ | 22m 11s | ||||||
| 10/10/24 | ![]() The Case for Chronic Pain Management among People Who Use Opioids | Are current guidelines failing chronic pain patients with a history of substance-use disorders? Find out why Dr. Wang and Dr. Kelly are calling for urgent policy changes and how updated guidelines can support effective pain management. Join us for a compelling discussion on the intersection of chronic pain and substance use disorders with insights from Dr. Linda Wang, Medical Director of CEI's Hepatitis C and Drug User Health Center, and Dr. Lauren Kelly, a geriatrician and palliative care provider at Mount Sinai. We explore the complex case of a 62-year-old woman who, after decades of sobriety, began experiencing severe, undiagnosed pain. Despite numerous consultations and non-opioid treatments, her pain remained unmanaged, leading her to self-medicate with heroin. We discuss the significant barriers she faced in seeking appropriate care, including the reluctance of prescribers to provide methadone due to her history of opioid use disorder. Dr. Wang and Dr. Kelly discuss the importance of understanding patients' substance use patterns and the benefits of treatments like methadone and buprenorphine for stability and safety. We also cover non-opioid treatments such as physical therapy, acupuncture, and emerging modalities like scrambler therapy. The conversation emphasizes addressing the psychological aspects of pain and tackling the pervasive issue of stigma that impacts patients' access to necessary treatments. Finally, we delve into the critical issue of prescribing controlled substances to individuals with a history of addiction, shedding light on the gaps in current guidelines and the stigma within the healthcare system. Dr. Wang and Dr. Kelly stress the need for updated guidance to support chronic pain patients with substance use disorder, advocating for compassionate, individualized care. Related Content: Rules and Regulations on Controlled Substances in NYS CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/ | 46m 50s | ||||||
| 9/10/24 | ![]() An Exciting New Twice-yearly Option for HIV PrEP | “This podcast discusses the recent presentation of data for lenacapavir, a potent capsid inhibitor for HIV that was 100% effective in preventing HIV infection in cis-gender woman at risk for HIV. If approved, it will offer an exciting new option to prevent HIV which should dramatically improve our chances of reaching the goal of totally eliminating new HIV infections. The trial compared twice yearly injections of lenacapavir to both F/TAF and F/TDF in cis-gender woman and found similar effectiveness for F/TAF compared to F/TDF but there were zero new HIV infections in participants on lenacapavir.”. Related Content: The New England Journal of Medicine. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. Authors: Linda-Gail Bekker, M.B., Ch.B, Ph.D. https://orcid.org/0000-0002-0755-4386, Moupali Das, M.D., M.P.H., Quarraisha Abdool Karim, Ph.D. https://orcid.org/0000-0002-0985-477X, Khatija Ahmed, M.B., B.Ch., Joanne Batting, M.B., Ch.B., D.F.S.R.H., D.R.C.O.G., Dip. HIV Man., William Brumskine, M.B., Ch.B., Dip. HIV Man., Katherine Gill, M.B., Ch.B., M.P.H., +33, for the PURPOSE 1 Study Team*Author Info & Affiliations. Published July 24, 2024. DOI: 10.1056/NEJMoa2407001 CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/ | 13m 35s | ||||||
| 8/8/24 | ![]() When HIV Tests Perplex: Expert Insights on Ambiguous and Discordant Results | Providers calling into our CEI hotline often ask me what to do when their patient's HIV test results are unclear. These ambiguous or discordant test results can be a source of anxiety and confusion for both patients and healthcare providers alike. To provide additional insight into this complex issue, Dr. Tony Urbina, Professor of Medicine from Mt. Sinai Health System and Medical Director of the New York State CEI HIV Primary Care and Prevention Center of Excellence, speaks with Dr. Lucia Torian, a distinguished epidemiologist who has dedicated over three decades of her career to the New York City Department of Health. As the Deputy Director of the HIV Epidemiology Program, she brings a wealth of expertise in HIV diagnostic testing and case surveillance. In our conversation, we dive into real-world scenarios that illustrate the challenges of interpreting HIV test results. We explore real-world cases involving early exposure, false positives, and the added complications of testing migrant populations. The discussion includes practical advice on managing patient anxiety, effective communication strategies, and navigating ambiguous results. Listeners will gain insights into testing acute infections, how to handle PrEP ambiguity, and the role of advanced diagnostic techniques like Western blot tests. Additionally, Dr. Torian shares her thoughts on whether ambiguous results are becoming more prevalent in NYC and provides recommendations for follow-up procedures and timing. Tune in for a comprehensive look at improving HIV testing accuracy and patient care. Related Content: CDC HIV Nexus -- https://www.cdc.gov/hivnexus/hcp/prep/index.html#:~:text=If%20results%20are%20discordant%20or,until%20HIV%20status%20is%20confirmed. AIDS Institute PrEP guidance including diagnostic testing -- https://www.hivguidelines.org/guideline/hiv-prep/ NY State Wadsworth Center -- https://www.aphl.org/conferences/proceedings/Documents/2018/43_Gaynor_Parker.pdf APHL -- https://www.aphl.org/aboutAPHL/publications/Documents/ID-2019Jan-HIV-Lab-Test-Suggested-Reporting-Language.pdf CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/ | 29m 08s | ||||||
Showing 25 of 64
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.
